If you are living with depression that has not improved with traditional antidepressants, you may feel frustrated, discouraged, or unsure what to try next. SPRAVATO® offers a different path forward. At The Grant Group, you receive experienced care in a supportive setting to help you move toward lasting relief.
Below are answers to common SPRAVATO FAQs and how it may fit into your treatment plan.
SPRAVATO is the brand name for esketamine, a prescription nasal spray cleared by the FDA for adults with treatment-resistant depression and for certain adults with major depressive disorder who have suicidal thoughts or actions. Unlike standard antidepressants that primarily target serotonin, SPRAVATO works on the brain’s glutamate system, which plays a key role in mood regulation.
Because of its unique mechanism, SPRAVATO may help when other medications have not provided adequate improvement.
You may be a candidate if you have tried at least two different antidepressants without meaningful relief. SPRAVATO is typically prescribed alongside an oral antidepressant. During your evaluation at The Grant Group, we carefully review your medical history, previous treatments, and current symptoms to determine whether SPRAVATO is appropriate for you.
This therapy is not suitable for everyone. Certain medical conditions, including uncontrolled high blood pressure or a history of certain vascular issues, may require additional screening or alternative approaches.
Traditional antidepressants can take several weeks to begin working. SPRAVATO may produce improvement more quickly for some individuals because it targets glutamate, a different neurotransmitter pathway than most oral medications.
SPRAVATO is a nasal spray you give yourself under medical supervision in the office. You do not take the medication at home. After each session, you stay in the clinic for monitoring, typically for about two hours, so your care team can ensure your safety and comfort.
Your first phase of treatment usually involves twice-weekly sessions for several weeks, followed by a gradual reduction in frequency depending on your response. Your appointment takes place in a calm environment.
During treatment, you may experience temporary side effects such as dizziness, nausea, mild dissociation, or increased blood pressure. These effects typically resolve the same day. Because SPRAVATO can affect alertness, you will need someone to drive you home after each session.
We monitor your progress closely, including your mood, safety, and overall response, at regular intervals to ensure the treatment is benefiting you.
SPRAVATO is available only through a Risk Evaluation and Mitigation Strategy program required by the FDA. This means it must be administered in a certified medical office, and patients are observed after each dose.
The Grant Group provides your medication in a supervised setting. This ensures that SPRAVATO has an established safety profile. We review potential risks, benefits, and alternatives so you can make an informed decision.
Every person responds differently. Some patients notice improvement within weeks, while others may require a longer course of treatment. The goal is sustained symptom relief, not just short-term improvement. Ongoing communication with your provider helps ensure adjustments are made if needed.
If you feel stuck despite multiple treatment attempts, you deserve to explore options backed by research and clinical oversight. SPRAVATO offers a science-driven alternative for adults with difficult-to-treat depression.
We hope these Spravato FAQs have helped answer your questions and clarify what to expect from treatment. At The Grant Group, your care is individualized, compassionate, and grounded in evidence-based practice. If you have questions about whether SPRAVATO is right for you, schedule a consultation and take the next step toward meaningful change.